Management of Spinal Surgery in Severe Hemophilia B under Marstacimab Prophylaxis
Hämostaseologie · 13.11.2026
DOI: 10.1055/a-2987-1774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 13.11.2026. Verfasst von Christian Pfrepper und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital Leipzig, Division of Hemostaseology, SN, Germany, Le….
Abstract (Originalsprache)
AbstractMarstacimab is an antibody directed against tissue factor pathway inhibitor aiming to rebalance hemostasis in patients with severe hemophilia. There are currently no reports on the management of patients under marstacimab prophylaxis undergoing major surgeries outside clinical trials. We report a patient with severe hemophilia B and a history of myocardial infarction who underwent major elective spinal surgery followed by urgent revision surgery while receiving marstacimab prophylaxis. For the first operation, the last dose of marstacimab was administered 12 days before surgery and plasma-derived factor (F) IX was administered to achieve a trough level of 50 IU/dL to maintain hemostasis. For the second operation, performed only seven days after the last marstacimab dose, the trough level was reduced to 30 IU/dL to limit the potential additive prothrombotic effect of both agents, as relevant residual marstacimab concentrations were expected. No relevant bleeding occurred. To prevent thrombotic complications, both surgeries were performed under thromboprophylaxis with low molecular weight heparin, and acetylsalicylic acid was continued. Thrombin generation was normalized under marstacimab and equal or higher than with 54 IU/dL FIX activity depending on the assay. This supports our strategy of providing sufficient FIX replacement while minimizing thrombotic risk. Due to the long half-life of marstacimab, low factor trough levels may be sufficient to provide adequate hemostasis in patients undergoing major surgeries.
Autor:innen und Institutionen
- Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital Leipzig, Division of Hemostaseology, SN, Germany, Leipzig.
- Charite - Universitatsmedizin Berlin, Institute of Transfusion Medicine, BE, Germany, Berlin.
- MVZ Limbach Magdeburg, Zentrum für Blutgerinnungsstörungen und Gefäßkrankheiten, Germany, Magdeburg.
ORCID-Profile: Christian Pfrepper
Zitieren
APA
Pfrepper, C., Weise, M., Kalus, U., Siegemund, A., Siegemund, T., & Klöter, T. (2026). Management of Spinal Surgery in Severe Hemophilia B under Marstacimab Prophylaxis. Hämostaseologie. https://doi.org/10.1055/a-2987-1774
Vancouver
Pfrepper C, Weise M, Kalus U, Siegemund A, Siegemund T, Klöter T. Management of Spinal Surgery in Severe Hemophilia B under Marstacimab Prophylaxis. Hämostaseologie. 2026. doi:10.1055/a-2987-1774
BibTeX
@article{Pfrepper2026,
author = {Pfrepper, Christian and Weise, Maria and Kalus, Ulrich and Siegemund, Annelie and Siegemund, Thomas and Klöter, Tristan},
title = {Management of Spinal Surgery in Severe Hemophilia B under Marstacimab Prophylaxis},
journal = {Hämostaseologie},
year = {2026},
doi = {10.1055/a-2987-1774}
}
EUVIMED